Design Therapeutics, Inc. DSGN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s stock-based comp?
- Design Therapeutics, Inc. (DSGN) reported stock-based comp of $3.92M in Q1 2026.
- How has Design Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Design Therapeutics, Inc.'s stock-based comp increased by 10.9% year-over-year, from $3.54M to $3.92M.
- What is the long-term trend for Design Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s stock-based comp has grown at a 32.7% compound annual growth rate (CAGR), from $4.69M to $14.55M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.